Cargando…
Novel benzoxaborole, nitroimidazole and aminopyrazoles with activity against experimental cutaneous leishmaniasis
OBJECTIVES: Drugs for Neglected Diseases initiative (DNDi) has identified three chemical lead series, the nitroimidazoles, benzoxaboroles and aminopyrazoles, as innovative treatments for visceral leishmaniasis. The leads discovered using phenotypic screening, were optimised following disease- and co...
Autores principales: | Van Bocxlaer, Katrien, Caridha, Diana, Black, Chad, Vesely, Brian, Leed, Susan, Sciotti, Richard J., Wijnant, Gert-Jan, Yardley, Vanessa, Braillard, Stéphanie, Mowbray, Charles E., Ioset, Jean-Robert, Croft, Simon L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6904836/ https://www.ncbi.nlm.nih.gov/pubmed/30922847 http://dx.doi.org/10.1016/j.ijpddr.2019.02.002 |
Ejemplares similares
-
Route map for the discovery and pre-clinical development of new drugs and treatments for cutaneous leishmaniasis
por: Caridha, Diana, et al.
Publicado: (2019) -
Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake
por: Espada, Caroline R., et al.
Publicado: (2019) -
In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis
por: Sengupta, Ritika, et al.
Publicado: (2019) -
Mining for natural product antileishmanials in a fungal extract library
por: Mbekeani, A.J., et al.
Publicado: (2019) -
Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles
por: Sousa-Batista, Ariane J., et al.
Publicado: (2019)